Supraoptimal peptide-major histocompatibility complex causes a decrease in Bcl-2 levels and allows tumor necrosis factor α receptor II-mediated apoptosis of cytotoxic T lymphocytes

Journal of Experimental Medicine

Volumn 188, Issue 8, 1998, Pages 1391-1399

  Alexander Miller, Martha A ^a,c   Derby, Michael A ^a   Sarin, Apurva ^b   Henkart, Pierre A ^b   Berzofsky, Jay A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Proteins c bel 2; Protooncogene; T lymphocytes, cytotoxic; Tumor necrosis factor

Indexed keywords

CASPASE; MAJOR HISTOCOMPATIBILITY ANTIGEN; PROTEIN BCL 2; PROTEINASE; SYNTHETIC PEPTIDE; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNOBLOTTING; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; SPLEEN CELL; VIRUS INFECTION;

ANIMALS; ANTIGENS; APOPTOSIS; CASPASES; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, TUMOR NECROSIS FACTOR; T-LYMPHOCYTES, CYTOTOXIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032547813     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.188.8.1391     Document Type: Article

References (39)

1. Mitchison, N.A. 1964. Induction of immunological paralysis in two zones of dosage. Proc. R. Soc. Ser. B. 1964:275-292.
2. Moskophidis, D., F. Lechner, H. Pircher, and R.M. Zinkernagel. 1993. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature. 362:758-761.
3. Hoffenbach, A., P. Langlade-Demoyen, G. Dadaglio, E. Vilmer, F. Michel, C. Mayaud, B. Autran, and F. Plata. 1989. Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans. J. Immunol. 142:452-462.
4. Carmichael, A., X. Jin, P. Sissons, and L. Borysiewicz. 1993. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J. Exp. Med. 177:249-256.
5. + T lymphocytes of patients with AIDS maintain normal broad cytolytic function despite the loss of human immunodeficiency virus-specific cytotoxicity. Proc. Natl. Acad. Sci. USA. 87:4818-4822.
6. Alexander-Miller, M.A., G.R. Leggatt, and J.A. Berzofsky. 1996. Selective expansion of high or low avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA. 93:4102-4107.
7. Alexander-Miller, M.A., G.R. Leggatt, A. Sarin, and J.A. Berzofsky. 1996. Role of antigen, CD8, and CTL avidity in high dose antigen induction of apoptosis of effector CTL. J. Exp. Med. 184:485-492.
8. Zheng, L., G. Fisher, R.E. Miller, J. Peschon, D.H. Lynch, and M.J. Lenardo. 1995. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature. 377:348-351.
9. Hogquist, K.A., S.C. Jameson, W.R. Heath, J.L. Howard, M.J. Bevan, and F.R. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. Cell. 76:17-27.
10. Jameson, S.C., K.A. Hogquist, and M.J. Bevan. 1994. Specificity and flexibility in thymic selection. Nature. 369:750-752.
11. Smith, C.A., T. Farrah, and R.G. Goodwin. 1994. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell. 76:959-962.
12. Wang, C.-Y., M.W. Mayo, and A.S. Baldwin, Jr. 1996. TNF-and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science. 274:784-787.
13. Hsu, H., J. Xiong, and D.V. Goeddel. 1995. The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation. Cell. 81:495-504.
14. Tartaglia, L.A., M. Rothe, Y.-F. Hu, and D.V. Goeddel. 1993. Tumor necrosis factor's cytotoxic activity is signaled by the p55 TNF receptor. Cell. 73:213-216.
15. Strasser, A. 1995. Life and death during lymphocyte development and function: evidence for two distinct killing mechanisms. Curr. Opin. Immunol. 7:228-234.
16. Stewart, J.M., and J.D. Young. 1984. Solid Phase Peptide Synthesis. Pierce Chemical Company, Rockford, Illinois.
17. Takeshita, T., H. Takahashi, S. Kozlowski, J.D. Ahlers, C.D. Pendleton, R.L. Moore, Y. Nakagawa, K. Yokomuro, B.S. Fox, D.H. Margulies, and J.A. Berzofsky. 1995. Molecular analysis of the same HIV peptide functionally binding to both a class I and a class II MHC molecule. J. Immunol. 154:1973-1986.
18. Takahashi, H., J. Cohen, A. Hosmalin, K.B. Cease, R. Houghten, J. Cornette, C. DeLisi, B. Moss, R.N. Germain, and J.A. Berzofsky. 1988. An immunodominant epitope of the HIV gp160 envelope glycoprotein recognized by class I MHC molecule-restricted murine cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA. 85:3105-3109.
19. Kozlowski, S., M. Corr, T. Takeshita, L.F. Boyd, C.D. Pendleton, R.N. Germain, J.A. Berzofsky, and D.H. Margulies. 1992. Serum angiotensin-1 converting enzyme activity processes an HIV 1 gp160 peptide for presentation by MHC class I molecules. J. Exp. Med. 175:1417-1422.
20. 2-microglobulin promotes functional peptide association with purified soluble class I MHC molecules. Nature. 349:74-77.
21. Sheehan, K.C.F., J.K. Pinckard, C.D. Arthur, L.P. Dehner, D.V. Goeddel, and R.D. Schreiber. 1995. Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75. J. Exp. Med. 181:607-617.
22. Sarin, A., D.H. Adams, and P.A. Henkart. 1993. Protease inhibitors selectively block T cell receptor-triggered programmed cell death in a murine T cell hybridoma and activated peripheral T cells. J. Exp. Med. 178:1693-1700.
23. Lenardo, M.J. 1991. Interleukin-2 programs mouse αβ T lymphocytes for apoptosis. Nature. 353:858-861.
24. Critchfield, J.M., M.K. Racke, J.C. Zúñiga-Pflücker, B. Cannella, C.S. Raine, J. Goverman, and M.J. Lenardo. 1994. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science. 263:1139-1143.
25. Critchfield, J.M., J.C. Zúñiga-Pflücker, and M.J. Lenardo. 1995. Parameters controlling the programmed death of mature mouse T lymphocytes in high-dose suppression. Cell. Immunol. 160:71-78.
26. Boehme, S.A., L. Zheng, and M.J. Lenardo. 1995. Analysis of the CD4 coreceptor and activation-induced costimulatory molecules in antigen-mediated mature T lymphocyte death. J. Immunol. 155:1703-1712.
27. Grell, M., E. Douni, H. Wajant, M. Löhden, M. Clauss, B. Maxeiner, S. Georgopoulos, W. Lesslauer, G. Kollias, K. Pfizenmaier, and P. Scheurich. 1995. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. 83:793-802.
28. Chinnaiyan, A.M., and V.M. Dixit. 1996. The cell-death machine. Curr. Biol. 6:555-562.
29. Nagata, S. 1996. Apoptosis: telling cells their time is up. Curr. Biol. 6:1241-1243.
30. Yuan, J. 1997. Transducing signals of life and death. Curr. Opin. Cell Biol. 9:247-251.
31. Sarin, A., M.-L. Wu, and P.A. Henkart. 1996. Different interleukin-1b converting enzyme (ICE) family protease requirements for the apoptotic death of T lymphocytes triggered by diverse stimuli. J. Exp. Med. 184:2445-2450.
32. Ware, C.F., S. VanArsdale, and T.L. VanArsdale. 1996. Apoptosis mediated by the TNF-related cytokine and receptor families. J. Cell. Biochem. 60:47-55.
33. Rothe, M., M.-G. Pan, W.J. Henzel, T.M. Ayres, and D.V. Goeddel. 1995. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell. 83:1243-1252.
34. Speiser, D.E., S.Y. Lee, B. Wong, J. Arron, A. Santana, Y.Y. Kong, P.S. Ohashi, and Y. Choi. 1997. A regulatory role for TRAF1 in antigen-induced apoptosis of T cells. J. Exp. Med. 185:1777-1783.
35. Nakayama, K.-i., K. Nakayama, I. Negishi, K. Kuida, Y. Shinkai, M.C. Louie, L.E. Fields, P.J. Lucas, V. Stewart, F.W. Alt, and D.Y. Loh. 1993. Disappearance of the lymphoid system in Bcl-2 homozygous mutant chimeric mice. Science. 261:1584-1588.
36. Reed, J.C., Y. Tsujimoto, J.D. Alpers, C.M. Croce, and P.C. Nowell. 1987. Regulation of bcl-2 proto-oncogene expression during normal human lymphocyte proliferation. Science. 236:1295-1299.
37. Chen, M., J. Quintans, Z. Fuks, C. Thompson, D.W. Kufe, and R.R. Weichseibaum. 1995. Suppression of Bcl-2 messenger RNA production may mediate apoptosis after ionizing radiation, tumor necrosis factor α, and ceramide. Cancer Res. 55:991-994.
38. Nunez, G., L. London, D. Hockenbery, M. Alexander, J.P. McKearn, and S.J. Korsmeyer. 1990. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J. Immunol. 144:3602-3610.
39. Gallimore, A., T. Dumrese, H. Hengartner, R.M. Zinkernagel, and H.G. Rammensee. 1998. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J. Exp. Med. 187:1647-1657.